The expanded approval was based on pediatric extrapolation of efficacy from adequate and well-controlled studies and pharmacokinetic data in adult heart transplant and liver transplant patients.
Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.
Moving to areas with low air pollution might improve outcomes for kidney transplant recipients, investigators suggested.
Patients with moderate and severe infection experienced a 17.50% and 23.16% decrease in estimated glomerular filtration rate (eGFR), respectively, from baseline (before testing positive for SARS-CoV-2) to 90 days after the positive test.
A study of patients who initiated dialysis in the Southeast United States found that those receiving care at for-profit facilities were 16% less likely to receive a kidney transplant referral than patients at non-profit facilities.
Analysis of United Network for Organ Sharing data reveals a declining trend in patients receiving a kidney from a living donor from 2010 to 2019.
Among patients with kidney failure, accounting for SES and comorbidity attenuates racial disparities in listing for, but not receipt of, kidney transplant.
The distance from a patient residence to transplant center seems not to impact transplant referral and evaluation initiation among those with end-stage kidney disease.
Kidney transplant graft failure is associated with additional medical costs of $78,079 for the average patient and a loss of 1.66 quality-adjusted life years (QALYs).
